Abstract
This article reviews current and emerging treatments for faecal incontinence (FI), focusing in particular on the innovative use of submucosal injection of dextranomer hyaluronic acid as a bulking agent. FI is a common condition that affects up to 21% of adults, and its severity increases with advancing age. It has a significant negative impact on patient quality of life, psychological wellbeing and social life. A variety of treatment modalities, including sacral nerve stimulation, have been shown to be effective in incontinence due to external anal sphincter dysfunction. However, treatment options for passive FI resulting from internal anal sphincter dysfunction are limited; a new injectable bulking agent offers a relatively minimally invasive and technically simple way to treat passive FI more effectively.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
